Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ATXS | Stock Option (right to buy) | Award | $0 | +1.4M | $0.00 | 1.4M | Jun 2, 2021 | Common Stock | 1.4M | $2.87 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | Represents the closing price of the common stock of Catabasis Pharmaceuticals, Inc. (the "Company") on April 1, 2021. |
F2 | This option was granted on April 1, 2021 subject to the approval by the stockholders of the Company of an increase in the number of shares of common stock available under the Company's Amended and Restated 2015 Stock Incentive Plan ("Proposal No. 4") at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"). Proposal No. 4 received the requisite approval at the Annual Meeting on June 2, 2021. The option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of April 1, 2021 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. |